Pull to refresh
Logo
At-home urine test spots bladder cancer in nine of ten NHS cases

At-home urine test spots bladder cancer in nine of ten NHS cases

New Capabilities

GALEAS Bladder caught 92% of cancers in a 964-patient trial and could cut the need for invasive cystoscopy

4 days ago: Trial results published: 92.2% of bladder cancers detected

Overview

Updated 4 days ago

A urine test patients can take at home caught more than nine in ten bladder cancers in an NHS trial of 964 patients. The GALEAS Bladder test detected all muscle-invasive cancers and carried a 99.3% chance the patient was clear when it returned a negative result.

The test reads DNA shed into urine for mutations across 23 genes linked to bladder cancer. It works as a triage tool: a positive result pushes patients to the front of the line for urgent cystoscopy, while a negative result lets lower-risk patients defer the invasive camera procedure.

Why it matters

A UK-wide rollout could spare thousands of patients a year an invasive camera test and cut six-week waits many now face for a bladder cancer diagnosis.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

92.2%
Cancer detection sensitivity
Detected 71 of 77 bladder cancers in the trial.
99.3%
Negative predictive value
Chance a negative result means no bladder cancer.
100%
Muscle-invasive cancer detection
Caught all 17 muscle-invasive cancers and 97.2% of high-grade cancers.
730
Cystoscopies saved per 1,000 patients
Estimated reduction at the most cautious triage threshold with no loss of clinical benefit.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

October 2024 April 2027

5 events Latest: 4 days ago
Tap a bar to jump to that date
  1. West Midlands targets full regional adoption

    Upcoming Milestone

    All hospital trusts in the West Midlands are expected to offer GALEAS Bladder, per West Midlands Cancer Alliance commissioning.

  2. Trial results published: 92.2% of bladder cancers detected

    Latest Publication

    Study shows GALEAS caught 71 of 77 cancers, all muscle-invasive tumors, and carried a 99.3% negative predictive value.

  3. First NHS trust in England adopts GALEAS Bladder

    Rollout

    University Hospitals of Leicester becomes the first English trust to use the test; five hospitals have adopted it, 16 more planned.

  4. Trial completes enrollment at 964 patients

    Study milestone

    Enrollment ends; 77 of 964 patients are ultimately diagnosed with bladder cancer.

  5. Multicenter trial begins in seven NHS urology departments

    Study launch

    University of Birmingham study starts enrolling patients referred for urgent haematuria investigation.

Scenarios

1

NHS rolls out GALEAS Bladder as standard bladder cancer triage across England and Wales

Possible Resolves by Apr 30, 2027

Discussed by: University of Birmingham study team; West Midlands Cancer Alliance

The West Midlands meets its April 2027 target of all hospital trusts adopting the test. NHS England or NICE incorporates urine-based triage into haematuria referral guidance, expanding use beyond the five early adopters and 16 planned sites. The test becomes the routine first step before deciding who needs urgent cystoscopy.

2

NHS adoption stalls pending formal NICE appraisal

Possible Resolves by End of 2027

Discussed by: Birmingham study team interview on The Naked Scientists

Without a full NICE technology appraisal and randomized evidence, trusts adopt GALEAS at their own pace. Some continue cystoscopy-first pathways. The test remains available but confined to regions that commission it, and the estimated 730 cystoscopies saved per 1,000 patients stay unrealized nationally.

3

Nonacus launches second-generation GALEAS with higher sensitivity for early cancers

Possible Resolves by End of 2028

Discussed by: Birmingham study team on The Naked Scientists; Nonacus CEO Jeff Bousfield

A version two improves detection of small early tumors that shed little DNA into urine. Nonacus says a next version is in research. A release would push sensitivity above the current 92.2% and widen the gap over cystoscopy's 81% accuracy, strengthening the case for national adoption.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2003–2014

HPV DNA testing replaces cytology in cervical screening (2000s)

For decades, cervical cancer screening relied on the Pap smear, a subjective microscope examination of cells. The FDA approved the first HPV DNA test for co-testing in 2003, and by 2014 an HPV test was approved as a primary screening option.

Then

Clinics could triage women by infection status, cutting unnecessary procedures and repeat tests.

Now

Molecular testing became the standard of care, showing that objective DNA-based tests can outperform subjective cytology in population screening.

Why this matters now

GALEAS Bladder follows the same arc: an objective DNA test replacing a subjective, invasive procedure, with triage as the initial use case.

August 2014

Cologuard stool DNA test approved for colorectal cancer (2014)

The FDA approved Exact Sciences' Cologuard, an at-home stool test detecting DNA mutations and blood markers for colorectal cancer. It gave patients a non-invasive alternative to colonoscopy screening.

Then

Millions of patients who avoided colonoscopy could screen at home with a mail-in kit.

Now

Cologuard validated the regulatory and reimbursement path for at-home molecular cancer tests, later expanding to broader multi-cancer detection.

Why this matters now

GALEAS Bladder mirrors the Cologuard model: a home-administered DNA test that triages who truly needs an invasive scope, reducing procedural burden.

Sources

(11)